Kim Lorence H. sold $11.4M of RVMD (indirect holdings)
Kim Lorence H. sold 56,000 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $203.24 ($200.56–$206.15, $11.38M total) across 7 trades on 2026-08-31 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's $11.4M sale is the first public disclosure of this transaction, providing fresh data for traders.
Market read
Direct insider sell of a sizable amount may influence short‑term price action and sentiment in the biotech space.
What to watch
Potential upcoming clinical data or financing events not disclosed may be driving the sell.
Background
SEC Form 4 filing discloses insider transactions; required to be reported promptly.
Ticker impact
Director Kim Lorence H. sold 56,000 shares for $11.4M via a 10b5‑1 plan on 2026‑08‑31.
Potential short‑term pressure on RVMD, modest downside of 2‑4% in the next few days.
Large dollar amount relative to typical insider trades and use of a pre‑arranged plan suggest a material move, but no accompanying corporate event.
Market effects
Biotech sector may see slight bearish tilt as insider sell adds to perception of risk.
US biotech investors may adjust exposure; limited broader market effect.
Minimal global impact beyond RVMD shareholders.
Counterpoint
The sale could be routine portfolio diversification, not a red flag.
Key entities
- CompanyRevolution Medicines, Inc.
Biotech firm developing oncology therapies, ticker RVMD.
- InsiderKim Lorence H.
Director of Revolution Medicines, executing a 10b5‑1 sell plan.
